Dianthus price target raised to $98 from $81 at Jefferies

Jefferies analyst Maury Raycroft raised the firm’s price target on Dianthus (DNTH) to $98 from $81 and keeps a Buy rating on the shares after the company said the proportion of patients with improvement in adjusted INCAT is “substantially greater than 50%,” beating their bar of greater than or equal to 50% based on Part A open-label interim study results in its Phase 3 CAPTIVATE trial for chronic inflammatory demyelinating polyneuropathy.